Cleveland Diagnostics, a commercial-stage biotech, announced the launch of a public service announcement (PSA) this week ahead of the start of Prostate Cancer Awareness Month.

Rather, Cleveland Diagnostics announced the launch of a PSA for a PSA set to go live Friday.

The company’s A PSA on PSA campaign encourages patients, families and caregivers to download a fact sheet featuring educational information and resources regarding prostate cancer screenings, diagnoses and treatment options.

With every fact sheet download, the biotech will make a donation to the nonprofit Zero Prostate Cancer to fund research and support initiatives. Additionally, donations will be doubled by the nonprofit Golf Fights Cancer during the month. 

The prostate cancer push is a critical one as it is the most common cancer among American men as approximately one in eight men will be diagnosed with it during their lifetime. The American Cancer Society estimates that there are more than 288,000 new cases of prostate cancer each year and nearly 35,000 deaths from the disease.

As other healthcare organizations, including several notable pharma brands, have pointed out in recent years, early detection and treatment can make a significant difference in the fight against prostate cancer. 

“Our ‘A PSA on PSA’ campaign is a public service initiative designed to drive those important patient-provider conversations and get more patients screened for prostate cancer,” Cleveland Diagnostics CEO Arnon Chait, PhD said in a statement. “With increased education and awareness around accurate screening, we should be able to detect prostate cancer earlier and save more lives. And, through our partnership with Zero, we hope to continue to advance the field via important research and accessibility programs.”

The national campaign also ties in with the biotech’s next-generation diagnostic tests, including its novel IsoPSA test that is non-invasive, blood-based and can give patients insights into their PSA (prostate-specific antigen) levels. 

The company stated that a higher PSA level usually means additional testing, with “varying levels of invasiveness and accuracy ranging from blood tests to biopsies.”

The IsoPSA tests are available through the company or through Quest Diagnostics, which established a partnership with Cleveland Diagnostics earlier this year.

For a January 2024 article on Defense Secretary Lloyd Austin’s prostate cancer diagnosis, click here.